Efficacy and Survival-associated Factors with XXXX Combined with @entity900 and @entity136 for Advanced @entity1149 .

@entity1 @entity4562 @entity902 @entity294 @entity1149 @entity900 @entity3 @entity136
OBJECTIVE: To analyze the efficacy and survival associated factors of @entity4562 combined with @entity900 and @entity136 for advanced @entity1149 . MATERIALS AND METHODS: A total of 57 @entity1 with advanced @entity1149 ( @entity1149 ), who received @entity902 -based chemotherapy regimens for more than 1 cycle, were treated with @entity4562 combined with @entity900 and @entity136 until disease progression. Efficacy, survival time and adverse reactions were observed. The Kaplan-Meier method was adopted for analysis of survival and Cox regression for associated influencing factors. RESULTS: The @entity1 were followed up until October 31, 2013, and the median follow-up time was 19 months. Of 57 @entity1 , there were 4 (7.0%) with complete remission (CR), 8 (14.0%) with partial remission, 31 (54.4%) with stable disease, and 14 (24.6%) with disease progression. The remission rate was 21.1% and the disease control rate was 75.4%. The median progression-free survival (PFS) time and the median overall survival time were 10 months and 15.2 months. The one-year, two-year and three- year survival rates were 47.4%, 23.3% and 10.0%. Gender and pathological types were the independent risk factors influencing PFS time (P=0.028, P=0.009). Tumor pathological type and early efficacy were independent factors for the prognosis (P=0.018, P=0.000). Adverse reactions were mostly rashes of I~II degree and @entity294 and slightly increasing level of aminopherase. The skin adverse event incidence of III degree or above was 1.8% (1/57) and brain @entity3 was foudn in 31.6% (18/57). CONCLUSIONS: @entity4562 combined with @entity900 andgemcitabine, is effective for @entity1 with IIIb~IV @entity1149 who received multiple cycles of chemotherapy.
